Stock listing

Immutep Ltd

Selected listing: PRRUF · OTC · USD · US

Immutep Ltd (OTC:PRRUF), Health Technology. Latest release Sep 30, 2026: Immutep Receives A$0.86 Million R&D Tax Incentive.

PRRUF:OTCUSDUSUpdated September 25, 2026

Ticker: OTC:PRRUF
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: OTC
Currency: USD

About Immutep Ltd

The company focuses on developing innovative immunotherapy treatments for cancer and autoimmune diseases. Immutep is dedicated to advancing its research and clinical programs to improve patient outcomes.

Latest news from Immutep Ltd

Immutep Receives ~A$0.86 Million R&D Tax Incentive

September 30, 2026

Immutep : Receives ~A$0.86 Million R&D Tax Incentive

September 29, 2026

Change to American Depositary Share Ratio

September 21, 2026

Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)

September 11, 2026

Immutep Outlines Focused Development Strategy for Efti

September 10, 2026

All Immutep Ltd news →

Research Immutep Ltd

Immutep Ltd company profile

View the public company page for Immutep Ltd on 6ix.

Immutep Ltd news

Read company news and market updates connected to Immutep Ltd.

Immutep Ltd investor events

Find investor webinars, events, and replay context for Immutep Ltd.